Beam Therapeutics to present updated BEACON trial biomarker data for risto-cel in SCD at EHA2026

Beam Therapeutics

Beam Therapeutics

BEAM

0.00
  • Beam Therapeutics set updated biomarker data from Phase 1/2 BEACON trial of investigational autologous cell therapy risto-cel in sickle cell disease for presentation at European Hematology Association 2026 Congress on June 11-14, 2026.
  • New analyses are slated to show risto-cel restored red blood cell health and function, with improvements in sickling behavior and blood flow properties described as comparable to sickle cell trait.
  • Separate model-based meta-analysis is expected to reinforce link between higher fetal hemoglobin levels and better clinical outcomes in sickle cell disease, supporting risto-cel’s proposed mechanism and differentiation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120930PRIMZONEFULLFEED9717855) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.